NCT04579679 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 78
- units
- Participants
- groups
- description
- Patients with NET of lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG000
- title
- Cohort A (NET, Lung)
- description
- Patients with NET of small bowel origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG001
- title
- Cohort B (NET, Small Bowel)
- description
- Patients with NET of non-small bowel, non-pancreas, and non-lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG002
- title
- Cohort C (NET, Other)
- description
- Patients with NET of any origin received a single dose of drug cocktail (midazolam 2.5 mg, fexofenadine 30 mg and rosuvastatin 10 mg) on Day -2 followed by surufatinib 300 mg orally QD from C1D1 to C1D14. On C1D15, a single dose of surufatinib 300 mg and a single dose of drug cocktail as above was administered. Patients received surufatinib 300 mg orally QD from C1D16 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG003
- title
- Cohort D (NET, Any)
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.77
- value
- 63.5
- group Id
- BG001
- spread
- 10.44
- value
- 62.1
- group Id
- BG002
- spread
- 15.52
- value
- 57.3
- group Id
- BG003
- spread
- 7.40
- value
- 63.5
- group Id
- BG004
- spread
- 12.37
- value
- 61.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 40
- title
- Female
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 38
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 3
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 60
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 59
- title
- White
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 12
- title
- Not Reported
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Other
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- title
- Missing
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The safety analysis set included all patients who received at least 1 dose of surufatinib.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 78
- units
- Participants
- groups
- description
- Patients with NET of lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG000
- title
- Cohort A (NET, Lung)
- description
- Patients with NET of small bowel origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG001
- title
- Cohort B (NET, Small Bowel)
- description
- Patients with NET of non-small bowel, non-pancreas, and non-lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG002
- title
- Cohort C (NET, Other)
- description
- Patients with NET of any origin received a single dose of drug cocktail (midazolam 2.5 mg, fexofenadine 30 mg and rosuvastatin 10 mg) on Day -2 followed by surufatinib 300 mg orally QD from C1D1 to C1D14. On C1D15, a single dose of surufatinib 300 mg and a single dose of drug cocktail as above was administered. Patients received surufatinib 300 mg orally QD from C1D16 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.
- id
- BG003
- title
- Cohort D (NET, Any)
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.77
- value
- 63.5
- group Id
- BG001
- spread
- 10.44
- value
- 62.1
- group Id
- BG002
- spread
- 15.52
- value
- 57.3
- group Id
- BG003
- spread
- 7.40
- value
- 63.5
- group Id
- BG004
- spread
- 12.37
- value
- 61.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 40
- title
- Female
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 38
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 3
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 60
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 59
- title
- White
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 12
- title
- Not Reported
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Other
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- title
- Missing
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The safety analysis set included all patients who received at least 1 dose of surufatinib.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle